Therapeutic applications of nucleic acids as ligands for toll-like receptors

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 2, 2009, Pages 133-145

  Panter, Gabriela ^a   Kužnik, Alenka ^a   Jerala, Roman ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Adjuvant; Autoimmune disease; Cancer; Infectious disease; Nucleic acid; SiRNA; TLR

Indexed keywords

AGATOLIMOD; AMPLIGEN; AMPLIVAX; ANTHRAX VACCINE; ANTIALLERGIC AGENT; ANTIVIRUS AGENT; AVE 0675; BCG VACCINE; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CPG 10101; CPG 52364; CPG 9328; CYT 004; DV 1079; HEPATITIS B VACCINE; HSP E7; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYB 2125; IC 31; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; IMO 2055; IMO 2125; IMO 3100; INFLUENZA VACCINE; IR 103; ISS 1018; NUCLEIC ACID; PEGINTERFERON ALPHA; PF 676; QAX 935; RIBAVIRIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE; YELLOW FEVER VACCINE; YF 17D;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTHRAX; ARTIFICIAL EMBOLISM; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPETITIVE INHIBITION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; GLIOBLASTOMA; HAY FEVER; HEPATITIS B; HEPATITIS C; HOUSE DUST ALLERGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION; INFLUENZA; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MIXED INFECTION; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PERENNIAL RHINITIS; PROTEIN TARGETING; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VIREMIA; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-ALLERGIC AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; MODELS, BIOLOGICAL; NUCLEIC ACIDS; TOLL-LIKE RECEPTORS;

EID: 63849285296     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Kawai T, Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci (2008) 1143:1-20.
2. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499-511.
3. Gilliet M, Cao W, Liu YJ: Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 8(8):594-606.
4. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 2(10):947-950.
5. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-αB by toll-like receptor 3. Nature (2001) 413(6857):732-738.
6. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 303(5663):1529-1531.
7. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-1529.
8. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
9. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3(2):196-200.
10. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR: Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science (2008) 320(5874):379-381.
11. Pirher N, Ivicak K, Pohar J, Bencina M, Jerala R: A second binding site for double-stranded RNA in TLR3 and consequences for interferon activation. Nat Struct Mol Biol (2008) 15(7):761-763.
12. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL: Proteolytic cleavage in an endolysosomal compartment is required for activation of toll-like receptor 9. Nat Immunol (2008) 9(12):1407-1414.
13. Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H: The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity (2008) 28(3):315-323.
14. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 14(10):1077-1087.
15. R̈nnblom L, Alm GV: Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther (2003) 5(2):68-75.
16. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME: Interferon a and its contribution to autoimmunity. Curr Opin Invest Drugs (2006) 7(5):451-456.
17. Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6(11):823-835.
18. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, Voll RE, Kalden JR, Herrmann M: Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun (2006) 9:173-187.
19. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, M̈r̈y T: Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet (2000) 25(2):177-181.
20. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y: Mutation of Dnase1 in people with systemic lupus erythematosus. Nat Genet (2001) 28(4):313-314.
21. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev (2005) 204:27-42.
22. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D: RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheum (2005) 52(9):2656-2665.
23. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA et al: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med (2005) 11(2):138-145.
24. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL: TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine (2005) 23(45):5263-5270.
25. Blander JM, Medzhitov R: On regulation of phagosome maturation and antigen presentation. Nat Immunol (2006) 7(10):1029-1035.
26. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B: Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 203(2):413-424.
27. Intercell AG: Novartis' Agrippal plus IC-31 safe in phase I influenza trial. Press Release (2008): February 27.
28. Hannaman D: Modern vaccines/adjuvants formulation - second international conference (Part II), Dublin, Ireland. IDDB Meeting Report (2007): November 12-14.
29. Hemispherx Biopharma Inc: Hemispherx Biopharma, Inc. completes enrollment in phase II study of Ampligen as seasonal flu vaccine enhancer. Press Release (2008): June 02.
30. Hemispherx Biopharma Inc: Esteve starts Spanish phase II Ampligen trial for HCV/HIV infection. Press Release (2005):January 04.
31. TM) met its primary endpoint. Press Release (2008): August 05.
32. Dynavax Technologies Corp: Dynavax and Merck & Co., Inc. report clinical hold of investigational vaccine HEPLISAV. Press Release (2008): March 17.
33. TM hepatitis B vaccine. Press Release (2009): February 09.
34. Orchestra Therapeutics Inc: Orchestra discontinues development of IR-103 and Remune HIV infection vaccines. Press Release (2007): July 18.
35. Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med (2007) 13(5):552-559.
36. Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull (2005) 28(5):886-892.
37. Spaner DE, Masellis A: Toll-like receptor agonists in in the treatment of chronic lymphocytic leukemia. Leukemia (2007) 21(1):53-60.
38. Jahrsd̈rfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ: Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol (2005) 77(3):378-387.
39. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T: Human lung cancer cells express functionally active toll-like receptor 9. Respir Res (2005) 6:1.
40. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 4(7):437-447.
41. Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I, Zeromski J: Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol (2007) 264(5):525-530.
42. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P: Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 13(15 Pt 1):4565-4574.
43. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T: TLR3 can directly trigger apoptosis in human cancer cells. J Immunol (2006) 176(8):4894-4901.
44. Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull (2005) 28(5):886-892.
45. Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ, Thumbikat P: The toll-like receptor pathway: A novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate (2008) 68(2):223-229.
46. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 67(7):774-781.
47. Innate Pharma SAS: Innate Pharma licenses TLR assets from Schering-Plough. Press Release (2006): June 19.
48. Coley Pharmaceutical Group Inc: Pfizer abandons PF-3512676 development for NSCLC. Press Release (2007): June 20.
49. Manegold C, Thatcher N, Benner RJ, Readett D, van Zandwijk N: Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (2008) 26:Abs-8017.
50. Shah S: American Society of Clinical Oncology - 41st Annual Meeting (Part III) - overnight report, Orlando, FL, USA. IDDB Meeting Report (2005): May 13-17.
51. Van Den Eertwegh AJM: Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-α for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol (2006) 24(18 Suppl):Abs 2530.
52. Witzig TE, Wiseman GA, Weiner G, Ansell SM: A phase I trial of CpG-7909, rituximab immunotherapy, and Y90 zevalin radioimmunotherapy for patients (pts) with previously treated CD20+ non-Hodgkin lymphoma (NHL). Am Soc Hematol Ann Meet Exposition (2007) 49:Abs 124.
53. Idera Pharmaceuticals Inc: Idera Pharma's IMO-2055 fails to meet primary endpoint in phase II renal carcinoma trial. Press Release (2008): October 01.
54. NV Organon: Drug development pipeline: Org-30659, Org-6370, Org-4428, rFSH, Organon, ganirelex, tibolone, mirtazapine, Trimiron, desogestrel, etonogestrel contraceptive implant, Organon, vaginal ring (contraceptive), Organon, Gracial, Org-33408, Org-32818, estradiol implant, Organon, dinoprostone, Organon, pipecuronium, BCG vaccine, Organon, danapariod sodium, SR-90107, rimexolone, Org-5222, Tri-Desogen, estradiol valerate, Orion, Org-12962, rapacuronium bromide. Company Communication (1996): October 10.
55. Krieg AM: Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc (2007) 4(3):289-294.
56. Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 79(11):7269-7272.
57. Sullivan T, Bhagat L, Trombino A, Cabral D, Agrawal S: IMO-2125, a TLR9 agonist that induces high interferon-a production, as a candidate for hepatitis C therapy. ICAAC (2007) 47:Abs F1-308.
58. Coley Pharmaceutical Group Inc: Coley suspends Actilon HCV infection development. Press Release (2007): January 22.
59. Heeg K, Dalpke A, Peter M, Zimmermann S: Structural requirement for uptake and recognition of CpG. Int J Med Micro (2008) 298(1-2):33-38.
60. Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH: Characterization of suppressive oligodeoxynucleotides that inhibit toll-like receptor-9-mediated activation of innate immunity. Immunology (2008) 123(1):118-128.
61. Klinman D, Shirota H, Tross D, Sato T, Klaschik S: Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol (2008) 84(4):958-964.
62. Ashman RF, Goeken JA, Drahos J, Lenert P: Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol (2005) 17(4):411-420.
63. Lenert P, Rasmussen W, Ashman RF, Ballas ZK: Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol (2003) 22(10):621-631.
64. Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA: The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol (2003) 170(7):3614-3620.
65. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF: Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol (2002) 32(5):1212-1222.
66. Lenert PS: Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther (2006) 8(1):203.
67. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, Barrat FJ: Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol (2005) 174(9):5193-5200.
68. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 202(8):1131-1139.
69. Barrat FJ, Coffman RL: Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev (2008) 223:271-283.
70. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL: Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol (2007) 37(12):3582-3586.
71. Idera Pharmaceuticals Inc: Idera Pharmaceuticals reports second quarter 2008 financial results. Press Release (2008): August 04.
72. Coley Pharmaceutical Group Inc: Coley's CPG-52364 enters phase I trial for SLE. Press Release (2008): October 29.
73. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 23(4):457-462.
74. Eberle F, Giessler K, Deck C, Heeg K, Peter M, Richert C, Dalpke AH: Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol (2008) 180(5):3229-3237.
75. Sioud M, Furset G, Cekaite L: Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun (2007) 361(1):122-126.
76. Judge A, MacLachlan I: Overcoming the innate immune response to small interfering RNA. Hum Gene Ther (2008) 19(2):111-124.
77. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 23(6):709-717.
78. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, Jarrossay D, Wagner H, Jung G, Rammensee HG, Hoerr I. et al.: Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol (2005) 35(5):1557- 1566.
79. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014):173-178.
80. Kariḱ K, Buckstein M, Ni H, Weissman D: Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity (2005) 23(2):165-175.
81. Agrawal S, Kandimalla ER: Synthetic agonists of toll-like receptors 7, 8 and 9. Biochem Soc Trans (2007) 35(Pt 6): 1461-1467.
82. Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF et al: Stabilized immune modulatory RNA compounds as agonists of toll-like receptors 7 and 8. Proc Natl Acad Sci USA (2007) 104(34):13750-13755.
83. Statens Serum Institut: SSI and Aeras start phase I TB trial of HyVac4-IC-31. Press Release (2007): December 05.
84. TM from Coley Pharmaceutical Group to expand its anthrax franchise. Press Release (2007): March 15.
85. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW: Safety and immunogenicity of CPG7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 22(23-24):3136-3143.
86. Orchestra Therapeutics Inc: Orchestra discontinues development of IR-103 and Remune HIV infection vaccines. Press Release (2007): July 18.
87. Cytos Biotechnology AG: Cytos's CYT004-MelQbG10 induces immune response in phase IIa melanoma trials. Press Release (2007): November 21.
88. von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T: Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology (2006) 211(6-8):557-565.
89. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X: A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501). Proc Am Soc Clin Oncol (2008) 26:Abs-2055.
90. Coley Pharmaceutical Group Inc: Coley Pharmaceutical group reports first quarter financial results. Press Release (2007): May 03.
91. Idera Pharmaceuticals Inc: Idera receives milestone from Novartis for phase I studies of QAX-935. Press Release (2008): September 02.
92. Cytos Biotechnology AG: CYT003-QbG10 monotherapy for the treatment of allergic diseases is safe and efficacious in placebo-controlled phase II study. Press Release (2008): July 09.
93. Cytos Biotechnology AG: Cytos's dust mite vaccine shows long-term efficacy. Press Release (2006): April 26.
94. Cytos Biotechnology AG: Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases. Press Release (2009): January 13.
95. Cytos Biotechnology AG: Cytos starts phase IIb trial of dust mite allergy vaccine. Press Release (2008): December 10.
96. Idera Pharmaceuticals Inc: Idera's TLR-7 and TLR-9 antagonists effective in preclinical RA studies. Press Release (2007): July 17.